Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | HTR3A | P46098 | 8/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.66 |
| ▸ | HTR3E | A5X5Y0 | 7/20 | 0.65 |
| ▸ | HTR3B | O95264 | 7/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 7/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 7/20 | 0.65 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.65 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.65 |
| ▸ | CHRNG | P07510 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.65 |
| ▸ | CHRND | Q07001 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mdl-74156 SCHEMBL7281981 | 1.00 | KCNH2 (1.00) | KCNH2HTR3ASLC6A4HTR3EHTR3B | |
| Mdl-74156 SCHEMBL8339181 | 1.00 | KCNH2 (1.00) | KCNH2HTR3ASLC6A4HTR3EHTR3B | |
| Mdl-74156 SCHEMBL10512437 | 0.82 | HTR3A (0.68) | KCNH2HTR3ASLC6A4HTR3EHTR3B | |
| SCHEMBL7289186 | 0.81 | HTR3A (0.71) | KCNH2HTR3ASLC6A4HTR3EHTR3B | |
| SCHEMBL8323170 | 0.81 | KCNH2 (0.68) | KCNH2HTR3ASLC6A4HTR3EHTR3B | |
| SCHEMBL8323177 | 0.81 | KCNH2 (0.68) | KCNH2HTR3ASLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL24914047 | 0.80 | HTR3A (1.00) | KCNH2HTR3ASLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL1819896 | 0.80 | HTR3A (1.00) | KCNH2HTR3ASLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL20769824 | 0.80 | HTR3A (1.00) | KCNH2HTR3ASLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL1819898 | 0.80 | HTR3A (1.00) | KCNH2HTR3ASLC6A4HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956025-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | Allergan Sales, LLC (US) | 2022-02-23 | — | — | EP | claimed |
| US-20260114973-A1 | INTRA-RUMINAL DEVICE | ARGENTA INNOVATION LTD (NZ) | 2026-04-30 | — | — | US | disclosed |
| US-12521221-B2 | Intra-ruminal device | ARGENTA INNOVATION LIMITED (NZ) | 2026-01-13 | — | — | US | disclosed |
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | PFIZER IRELAND PHARMACEUTICALS | 2024-12-12 | — | — | US | disclosed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| EP-4427793-A2 | INTRA-RUMINAL DEVICE | Argenta Innovation Limited (NZ) | 2024-09-11 | — | — | EP | disclosed |
| EP-3758647-B1 | INTRA-RUMINAL DEVICE | ARGENTA INNOVATION LTD (NZ) | 2024-07-31 | — | — | EP | disclosed |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-02-29 | — | — | US | disclosed |
| EP-4302828-A2 | COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES | Allergan Pharmaceuticals International Limited (IE) | 2024-01-10 | — | — | EP | disclosed |
| EP-4076395-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-10-26 | — | — | EP | disclosed |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2022165291-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-4034156-A1 | COMBINATION THERAPY WITH CGRP ANTAGONISTS | Allergan Pharmaceuticals International Limited (IE) | 2022-08-03 | — | — | EP | disclosed |
| US-20220218717-A1 | PROCESS FOR MANUFACTURING SOFT CHEWABLE FREE FLOWING GRANULES AND COMPANION ANIMAL PRODUCTS THEREOF | CUCKOS PHARMACEUTICAL PRIVATE LIMITED (IN) | 2022-07-14 | — | — | US | disclosed |
| US-20220202938-A1 | TRANSDERMAL FORMULATIONS | ARGENTA INNOVATION LIMITED (NZ) | 2022-06-30 | — | — | US | disclosed |
| WO-2022132989-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022109077-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| EP-3956025-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | Allergan Sales, LLC (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | KCNH2 4204/4885HTR3A 4585/4885SLC6A4 4595/4885 |
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | CALCB, CALCA, CALCRL | KCNH2 1799/4885HTR3A 766/4885SLC6A4 780/4885 |
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | CALCA, CALCB, CALCRL | KCNH2 1053/4885HTR3A 88/4885SLC6A4 648/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | KCNH2 4204/4885HTR3A 4585/4885SLC6A4 4595/4885 |
| US-20260114973-A1 | INTRA-RUMINAL DEVICE | CRH, CRHR2, CRHR1 | KCNH2 4690/4885HTR3A 3207/4885SLC6A4 2676/4885 |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | MKI67, MYLK2, MYH2 | KCNH2 4204/4885HTR3A 4585/4885SLC6A4 4595/4885 |
| US-20220202938-A1 | TRANSDERMAL FORMULATIONS | NAPEPLD, CYP8B1, TSLP | KCNH2 2203/4885HTR3A 1105/4885SLC6A4 1619/4885 |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | MKI67, CDK4, CDKN1A | KCNH2 4100/4885HTR3A 3838/4885SLC6A4 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.